NCT00202787已完成2 期
Open-label, Phase II, Randomised, Pilot Study to Evaluate the Safety and Efficacy of Combination Therapy With Cetuximab and FOLFOX4 or FOLFOX4 Alone in Patients Colorectal Cancer and Initially Non-resectable
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)1 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2005年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 136
- 试验地点
- 1
- 主要终点
- Determine confirmed objective response rate
研究概览
简要总结
The purpose of this study is to determine confirmed objective response rate to combination therapy with cetuximab and FOLFOX4 or FOLFOX4 alone in patients with CRC and non-resectable hepatic metastases
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent.
- •Men and women < 75 years
- •Histologically confirmed diagnosis of CRC
- •Metastatic colorectal carcinoma with exclusive non-resectable hepatic metastases, due to fulfillment of one of the following criteria:
- •Number of hepatic metastases > or= 4;
- •Size of one or more hepatic metastases > 5 cm diameter;
- •Vascular involvement and/or poor site that prevent complete resection of hepatic disease and/or require resection with the remaining liver mass less than 25-30% of functional liver.
- •Presence of at least one lesion detectable by two-dimensional measurement.
- •Karnofsky functional status >or=70% at the time of enrollment in study
- •Life expectancy greater than 3 months.
- •Patients must not have received chemotherapy for advanced/metastatic disease.
- •Patients with the following characteristics will be enrolled:
- •Recurrence after adjuvant treatment with 5-fluorouracil/folinic acid or capecitabine +/- radiotherapy with disease-free period > 6 months following conclusion of treatment.
- •Recurrence after surgical and/or radiotherapy treatment without adjuvant systemic treatment.
- •De novo diagnosis of disease.
- •Proper liver function, defined by aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) < or = 2.5 x ULN (< or = 5 x ULN if there are hepatic metastases) and total bilirubin count < 1.5 x ULN.
- •Proper kidney function, defined as serum creatinine < 1.5 x ULN.
- •Proper hematological function, defined as neutrophil count > or = 1.5 x 109/l , platelets > or = 100 X 109/l and hemoglobin > or = 9 g/dl.
- •Effective birth control method for men as well as women if there is possibility of pregnancy
排除标准
- •Documented or suspected cerebral and/or leptomeningeal metastases.
- •Metastasis in any other non-hepatic site, including extrahepatic lymph node metastases.
- •Surgery (excluding biopsy for diagnosis) and/or radiotherapy within 4 weeks prior to enrollment in the study.
- •Participation in another clinical trial with medication in the past 30 days.
- •Chronic, concomitant administration of systemic immunotherapy, chemotherapy, hormone therapy or any other investigational drug.
- •Prior malignant tumour in past 5 years, except history of basal cell skin carcinoma or pre-invasive cervical carcinoma.
- •Any investigational drug during the 4 weeks prior to enrolment.
- •Prior administration of monoclonal antibodies, EGFR signal transduction inhibitors or EGFR-targeted treatment.
- •Prior participation in study in which treatment with cetuximab can be assigned (whether or not treatment with cetuximab is received)
- •Acute or subacute intestinal occlusion or history of inflammatory intestinal disease.
- •Evidence of grade 3 or 4 allergic reaction to any of the treatment components.
- •Clinically relevant peripheral neuropathy.
- •Clinically relevant myocardial disease or history of myocardial infarction in the past 12 months.
- •Known abuse of alcohol / drugs, Legal incapacity or limited legal capacity.
- •Any medical or psychological disorder which, in the opinion of the investigator, does not allow the patient to conclude the study or sign the informed consent.
- •Pregnant or nursing woman
研究组 & 干预措施
1
Experimental
FOLFOX-4+cetuximab
干预措施: FOLFOX-4+cetuximab (Drug)
2
Active Comparator
FOLFOX-4
干预措施: FOLFOX-4 (Drug)
结局指标
主要结局
Determine confirmed objective response rate
时间窗: 2005-2009
次要结局
- Determine safety of combination, surgical resectability and R0 resections, clinical benefit, time to disease progression, time to onset of response, duration of response, time to treatment failure, overall survival time(2005-2009)
- determination of polymorphisms of the intron 1 of the EGFR gene, TS, XRCC1, XPD, serum levels of EGFR and ATP7A and ATP7B, nº of copies of EGFR gene, the levels of PTEN, EGFR, AKT y MAPK proteins, and mutations at EGFR, PI3KCA, K-RAS y B-RAF genes(2005-2009)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.Metastatic Colorectal CancerNCT00531115Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)28
已完成
2 期
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT03662542Janssen Research & Development, LLC214
已完成
2 期
MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal CandidiasisVulvovaginal CandidiasisNCT01497223MethylGene Inc.220
已完成
2 期
A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naiveHepatitis C, ChronicNCT02993250Janssen Pharmaceutical K.K.33
尚未招募
3 期
Evaluating the Efficacy and Safety of Cleanser, Serum, and Sunscreen Products for Facial Redness.RednessNCT05961579Goldman, Butterwick, Fitzpatrick and Groff20